Pediatric primary central nervous system germ cell tumors of different prognosis groups show characteristic miRNome traits and chromosome copy number variations
- Hsei-Wei Wang†1, 2, 4, 5,
- Yu-Hsuan Wu†1,
- Jui-Yu Hsieh1,
- Muh-Lii Liang2, 6,
- Meng-En Chao6,
- Da-Jung Liu6,
- Ming-Ta Hsu3, 4 and
- Tai-Tong Wong6Email author
© Wang et al; licensee BioMed Central Ltd. 2010
Received: 25 September 2009
Accepted: 24 February 2010
Published: 24 February 2010
Intracranial pediatric germ cell tumors (GCTs) are rare and heterogeneous neoplasms and vary in histological differentiation, prognosis and clinical behavior. Germinoma and mature teratoma are GCTs that have a good prognosis, while other types of GCTs, termed nongerminomatous malignant germ cell tumors (NGMGCTs), are tumors with an intermediate or poor prognosis. The second group of tumors requires more extensive drug and irradiation treatment regimens. The mechanisms underlying the differences in incidence and prognosis of the various GCT subgroups are unclear.
We identified a distinct mRNA profile correlating with GCT histological differentiation and prognosis, and also present in this study the first miRNA profile of pediatric primary intracranial GCTs. Most of the differentially expressed miRNAs were downregulated in germinomas, but miR-142-5p and miR-146a were upregulated. Genes responsible for self-renewal (such as POU5F1 (OCT4), NANOG and KLF4) and the immune response were abundant in germinomas, while genes associated with neuron differentiation, Wnt/β-catenin pathway, invasiveness and epithelial-mesenchymal transition (including SNAI2 (SLUG) and TWIST2) were abundant in NGMGCTs. Clear transcriptome segregation based on patient survival was observed, with malignant NGMGCTs being closest to embryonic stem cells. Chromosome copy number variations (CNVs) at cytobands 4q13.3-4q28.3 and 9p11.2-9q13 correlated with GCT malignancy and clinical risk. Six genes (BANK1, CXCL9, CXCL11, DDIT4L, ELOVL6 and HERC5) within 4q13.3-4q28.3 were more abundant in germinomas.
Our results integrate molecular profiles with clinical observations and provide insights into the underlying mechanisms causing GCT malignancy. The genes, pathways and microRNAs identified have the potential to be novel therapeutic targets.
The reported incidence of primary germ cell tumors (GCTs) of central nervous system (CNS) in children is significantly higher in Taiwan, Japan and Korea compared to Western countries. The comparative incidences are 15.3% in Japan, 14.0% in Taiwan, 11.2% in Korea, 2.3% in USA, and 2.5% in German in various reported series [1–5]. There is still no explanation for this extreme geographic and ethnic difference between the three Asian series and the two Western series (p < 0.0001) . Genomic differences need to be considered and evaluated.
Primary CNS GCT consists of several subtypes with different degrees of histological differentiation and malignancy. According to histological differentiation, related tumor markers, and secreted protein markers, these tumors can be classified into germinomas and nongerminomatous GCTs (NGGCTs), the latter including embryonal carcinoma (EC), yolk sac tumors (YST), choriocarcinoma (CC), teratoma (mature teratoma, immature teratoma, or immature teratoma with malignant differentiation) and mixed GCTs . For NGGCTs, except for benign mature teratoma, all of the other tumors present with diverse malignancies and therapeutic sensitivities when compared to germinomas and are grouped together as nongerminomatous malignant GCTs (NGMGCTs). NGMGCTs require more extensive drug and irradiation treatment regimens, have a higher recurrence rate and a lower survival rate [7, 8]. Clinically, >50% of pediatric CNS GCTs are germinomas, while the majority of remaining tumors are NGMGCTs [5, 9]. Histologically, germinoma is the most undifferentiated GCT and is composed of undifferentiated large cells that resemble primordial germinal elements. Among the NGGCTs, the histological picture differs depending on the diagnosis. EC contains undifferentiated stem cells resembling the embryonic inner cell mass (ICM). YST and CC correspond to the extra-embryonic differentiation along mesoblast and trophoblast lines, respectively. This contrasts with teratomas, which consist of differentiated derivatives that include all three germ layers with or without incompletely differentiated tissue elements, like neuroepithelium, which resembles fetal tissue. CNS GCTs often present with more than one histological component and are then classified as mixed GCTs [7, 10, 11].
GCTs are presumed to arise from mutated primordial germ cells (PGCs) of genital ridge origin or dysfunction totipotent embryonic cells . Investigation of the different genetic compositions in ECs and ES cells may provide clues about the reduced dependency on external cues for self-maintenance that exist among GCTs, thereby benefiting tumorigenesis research on ECs as well as applications for human ES cells (see also a review article by Werbowetski-Ogilvie et al. ). Global gene expression studies in human embryonic stem cells and human pluripotent germ cell tumors have shown that the gene expression patterns of human ES cell lines are similar to those of the human embryonal carcinoma cell samples but are more distantly related to those of seminoma samples [12, 14]. Genes that are expressed at significantly greater levels in human ES and embryonal carcinoma cell lines than in control samples were pinpointed and are possible candidates for involvement in the maintenance of a pluripotent undifferentiated phenotype . Wnt and Notch pathway genes are overexpressed in the pluripotent human embryonal carcinoma cell line NTERA2 and in embryonic stem cells . These include members of the frizzled gene family (FZDI, FZD3, FZD4, FZD5, FZD6), which encodes receptors for the Wnt proteins, the Frizzled Related Protein family (SFRPI, SFRP2, FRZB, SFRP4), which encode soluble Wnt antagonists and also ligands and receptors of the Notch pathway (Dlkl, Jaggedl; Notchl, Notch2, Notch3) .
The histological differences between the various different GCTs are mirrored by their gene expression profiles [16, 17]. Genomic studies have been conducted on GCTs, most notably on Caucasian adult gonadal ones [12, 16]. However, only limited gene profiling studies have focused on primary pediatric CNS GCTs, and, to our knowledge, no transcriptome profiling work on Asian cases has been reported. A very recently paper studied global mRNA expression patterns in pediatric malignant GCTs arising from the testis, the ovary, the sacrococcygeal region and the brain, and then compared these with adult testicular tumors. These results showed that there is no segregation of GCTs with the same histology at different sites or at different ages, within the pediatric range. However, clear segregation of pediatric and adult tumors, most conspicuously among the YSTs, was observed . The pediatric seminomas are significantly enriched for genes associated with a self-renewing pluripotent phenotype, whereas the pediatric YSTs are significantly enriched for genes associated with differentiation and proliferation . These results suggest that the observed clinical differences between pediatric CNS GCTs from different ethnic backgrounds or prognosis groups may also be detected using genomic analysis.
MicroRNAs (miRNAs) are small RNAs of 18-24 nucleotides in length that are involved in the regulation of gene expression and hence a variety of biological processes through post-transcriptional RNA interference-based mechanisms. Matured miRNAs interact and inhibit target mRNAs and result in translational repression or mRNA cleavage [18–20]. In medulloblastoma (MB), an aggressive brain malignancy with a predominant incidence in childhood, a high throughput miRNA profiling analysis found that only a few miRNAs displayed upregulated expression, while most of them, such as miR-9 and miR-125a, were downregulated in the tumor samples, suggesting a tumor growth-inhibitory function . Moreover, the same group identified miRNAs downregulated in human MBs with high Hedgehog (Hh) signaling, which is one of the pathogenesis mechanisms of MB . Differential miRNAs, such as miR-184, have been identified and found to correlate with prognosis, differentiation, and apoptosis in pediatric neuroblastoma . A high-throughput miRNome analysis of adult gonadal GCTs has been published, and in each GCT subtype the miRNA patterns are quite different . For GCTs in children, only limited miRNA data has been reported.
Genomic copy number variation (CNV) in GCTs of adulthood has been extensively investigated. Gain of 12p in up to 80% of cases of adult testicular GCTs [25, 26]. In contrast, comparatively little genomic CNV investigation has been conducted on childhood GCTs. Using metaphase comparative genomic hybridization (CGH), a wide range of CNVs has been described in pediatric GCTs, including gains on 1q, 2p, 3, 7, 8, 13, 14, 20q, 21, and X, as well as losses on 1p36, 4q, 6q, 11, 13 and 18; but none are seen consistently [27–29]. This may due to either the heterogeneity of the GCTs, or the different algorithms that were applied to identify the CNV regions. In 2007, Palmer et al. used 34 GCTs (22 yolk sac tumors (YSTs), 11 germinomatous tumors and one metastatic embryonal carcinoma), which had occurred in children from birth to age 16, for CNV analysis. Most of their cases were from the testis, the ovary and the sacrococcygeal region and only two germinomas and one YST brain BCT were included . Gain of 12p was found to be present in 53% of primary MGCTs of children aged 5-16 and was also observed in four of fourteen YSTs affecting children less than 5 years old. The YSTs showed an increased frequency of 1p loss (p = 0.003), 3p gain (p = 0.02), 4q loss (p = 0.07) and 6q loss (p = 0.004) compared to the germinomatous tumors .
In this study, we applied genomic approaches to explore the molecular messages governing the ethnic and prognosis differences of CNS GCTs. Both mRNA and miRNome expression patterns were studied in pediatric primary CNS GCTs. To provide novel insights into GCT pathogenesis, the transcriptomes of all GCT cases were further compared to those of ES cell lines from both Caucasian and Taiwanese genetic backgrounds [12, 23]. Copy number variations (CNVs) in different GCT subtypes were also measured to evaluate their possible influence on gene expression traits. Finally, the transcriptomes of our patients were organized into functional modules in order to identify the dominant biological processes and key genes in the germinomas and NGMGCTs; this sought to help explain the clinical observations associated with these tumors.
Clinical aspects of primary pediatric CNS GCTs examined
In our series of 176 cases of primary pediatric CNS GCTs, 58.5% were germinoma and 41.5% were nongerminomatous GCTs (NGGCTs). Among the germinomas, 62.1% had a histological diagnosis, while the remaining 37.9% of cases had a presumptive diagnosis. For NGMGCTs, 90.3% had a histological diagnosis, with the remaining cases having a presumptive diagnosis. Each presumptive diagnosis of the GCTs was made according to the tumor's clinical features, neuroimaging results, serum tumor marker level (alpha fetal protein [AFP], beta human chorionic gonadotropin level [beta-hCG]) and response to radiotherapy and/or chemotherapy. Subtypes of NGGCTs included mature teratomas (5.1%), various NGMGCTs including immature teratomas, mixed GCTs, pure YSTs, and tumors diagnosed by tumor markers (35.2%), and unclassified GCTs (1.7%) (Additional file 1-A) The 5-year, 10-year and 15-year overall survival rates for the germinomas and NGMGCTs were 82.2%, 74.5% and 74.5% for the germinomas and 66.1%, 45.4% and 30.3% for the NGMGCTs.
The MicroRNA signatures associated with the different pediatric CNS GCT prognostic groups
Global miRNA expression patterns (the "miRNome") were analyzed in 12 cases (case 1-6, 12-14 & 16-18 in Additional file 1-B). Differentially expressed miRNAs that correlated with the germinoma group (GPG) and the NGMGCT group (IPG/PPG) were identified by 2-tailed Student's t-test with a significance level of p < 0.05 plus ≧2-fold changes. Their discrimination ability was assessed by principle component analysis (PCA). Thus, patients within the different prognosis groups were separated by their distinct miRNA profiles (Figure 1B). A heat map of these miRNAs indicates the unique expression levels associated with each prognostic group (Figure 1C). Two miRNAs (hsa-miR-142-5p and hsa-miR-146a) are enriched in the germinoma group (GPG) and 19 miRNAs are enriched in the NGMGCT group (IPG/PPG) (Figure 1C). The differential expression levels of the miRNAs across the two different histological categories and prognostic groups of the pediatric CNS GCTs were organized by array hybridization intensity (Figure 1D) and verified by quantitative PCR (qPCR) (Figure 1E). The expression levels of hsa-miR-142-5p, hsa-miR-335 and miR-654-3p were found to be different when the patients in these two different groups were compared (Figure 1D-E).
Stem cell traits associated with the expression patterns of protein-coding gene within the NGMGCT group
Top 50 known genes in TW germinomas.
Probe Set ID
ATPase; Ca++ transporting; ubiquitous
calcium binding tyrosine-(Y)-phosphorylation regulated
cytoplasmic polyadenylation element binding protein 1
chromosome X open reading frame 18
deleted in azoospermia-like
DNA-damage-inducible transcript 4-like
DEAD (Asp-Glu-Ala-Asp) box polypeptide 4
DEAD (Asp-Glu-Ala-Asp) box polypeptide 43
doublesex and mab-3 related transcription factor 1
developmental pluripotency associated 4
ELOVL family member 6; elongation of long chain fatty acids
endogenous retroviral family W; env(C7); member 1 (syncytin)
hypothetical protein FLJ25694
gastric inhibitory polypeptide
gametocyte specific factor 1
hect domain and RLD 5
histone cluster 1; H1c
histone cluster 1; H2bc
HORMA domain containing 1
potassium channel; subfamily V; member 2
LINE-1 type transposase domain containing 1
leucine zipper protein 4
lymphocyte antigen 75
maelstrom homolog (Drosophila)
melanoma antigen family B; 1
melanoma antigen family B; 2
methyl-CpG binding domain protein 2
matrix metallopeptidase 12 (macrophage elastase)
nuclear factor (erythroid-derived 2)-like 3
sperm equatorial segment protein 1
oxysterol binding protein-like 3
POU class 5 homeobox 1 pseudogene 3
PQ loop repeat containing 3
preferentially expressed antigen in melanoma
RAB7; member RAS oncogene family-like 1
spermatogenesis associated 22
serine/threonine kinase 31
synaptonemal complex protein 3
T-cell leukemia/lymphoma 1A
T-cell leukemia/lymphoma 1B
tudor domain containing 12
tudor and KH domain containing
Transcription factor CP2-like 1
transmembrane protein 170
undifferentiated embryonic cell transcription factor 1
WD repeat domain 21C
WD repeat domain 66
zinc finger protein 42 homolog (mouse)
Top 50 known genes in TW NGMGCTs.
Probe Set ID
ADAM metallopeptidase with thrombospondin type 1 motif; 5
cadherin 11; type 2; OB-cadherin (osteoblast)
collagen; type XIV; alpha 1
collagen; type I; alpha 1
collagen; type I; alpha 2
collagen; type XXI; alpha 1
Collagen; type III; alpha 1 (Ehlers-Danlos syndrome type IV)
collagen; type V; alpha 1
collagen; type V; alpha 2
cellular retinoic acid binding protein 2
chondroitin sulfate proteoglycan 2 (versican)
endothelin receptor type A
embryonal Fyn-associated substrate
fibrillin 2 (congenital contractural arachnodactyly)
FK506 binding protein 7
fibronectin leucine rich transmembrane protein 2
fibronectin leucine rich transmembrane protein 3
forkhead box P2
frizzled homolog 7 (Drosophila)
growth hormone receptor
glycosyltransferase 8 domain containing 2
GULP; engulfment adaptor PTB domain containing 1
H19; imprinted maternally expressed transcript
Meis homeobox 1
Meis homeobox 2
mesenchyme homeobox 2
midline 1 (Opitz/BBB syndrome)
odd-skipped related 2 (Drosophila)
platelet-derived growth factor receptor; alpha polypeptide
PDZ domain containing RING finger 3
periostin; osteoblast specific factor
Paired related homeobox 1
prostaglandin I2 (prostacyclin) synthase
protein tyrosine phosphatase; receptor type; D
Ras association (RalGDS/AF-6) domain family member 8
receptor tyrosine kinase-like orphan receptor 1
runt-related transcription factor 1; translocated to; 1
secreted frizzled-related protein 1
snail homolog 2 (Drosophila)
ST6 beta-galactosamide alpha-2;6-sialyltranferase 2
transforming growth factor beta 1 induced transcript 1
twist homolog 2 (Drosophila)
In the NGMGCT group (IPG/PGG), genes involved in cell adhesion and migration, such as cadherin 11 (CDH11) and various collagens, are abundantly expressed (Table 2, labeled by asterisks). SNAI2 (alias SLUG) and TWIST2, two key regulators involved in neural crest development and epithelial-mesenchymal transition (EMT), are also highly expressed in this group; these proteins are known to contribute heavily to cell motility and tumor metastasis . Finally, genes such as FZD7 and SFRP1, which are involved in the Wnt signaling pathway, are also highly expressed (Table 2).
It has been recognized that aggressive and poor prognostic glioblastomas, as well as other tumors, acquire characters reminiscent of embryonic stem cells (ESCs) and the degree of ESC gene expression correlates with patient prognosis . It is possible that pediatric CNS GCTs, especially the poor prognosis NGMCGTs, are reminiscent of ES cells. We compared the gene expression patterns of pediatric GCTs to those of Caucasian and Taiwanese ESC lines. PCA analysis showed that NGMGCTs have a closer relationship to ES cells (Figure 2B). The ESC array data from five different data sets (GSE7234, GSE7896, GSE9440 (for the Taiwanese ESC lines) and GSE9832 and GSE13828 (for the Caucasian ESC lines) were all grouped together (Figure. 2B) and possible batch effects during array analysis were ignored. To provide quantitative insights, we calculated the relationships between the GCT subgroups and the ESCs by measuring the average linkage Euclidean distances between them. NGMGCTs were found to closer to the ESC than the germinomas (Figure. 2C).
The closer relationship between NGMGCTs and ESCs was verified further by hierarchical clustering. As shown in Figure. 2D, clearly the NGMGCTs and ESCs form one group while the germinomas form another. In total, 100 genes commonly show high-expression between NGMGCTs and ESCs (Figure. 2D). Among these genes the following are notable. IRS1 (Insulin receptor substrate 1) is an effector of sonic hedgehog mitogenic signaling in cerebellar neural precursors  and regulates murine embryonic stem cell self-renewal  (Figure. 2D, underlined and in bold). MID1 is a RING finger transcription factor involved in Opitz syndrome and is expressed strongly in undifferentiated cells in the central nervous system as well as the gastrointestinal and respiratory tract epithelium of human embryos . Embryonic oncogenes such as NET1 (neuroepithelial cell transforming gene 1), HIF3A (hypoxia inducible factor 3, alpha subunit), ETS2, RUNX1T1, and the Wnt signaling pathway genes (FZD7 and SFRP1) also appear in this cluster (Figure. 2D). However, notably, two key EMT genes, SNAI2 (SLUG) and TWIST2, are uniquely expressed by NGMGCTs (Figure. 2D).
Among the genes commonly found to show abundant expression in both the ESCs and germinomas, the pluripotent stemness genes DPP4 and POU5F1 (OCT4) are significant (Figure. 2D, underlined and in bold). The array hybridization signal for POU5F1 is shown in Figure. 2E. The high expression of POU5F1, as well as that of another stemness gene NANOG in germinomas, was verified by qPCR (Figure 2F). In contrast, SNAI2 (SLUG) is overexpressed in NGMGCTs (Figure 2E-F).
Relationships between abundant microRNAs and their target mRNAs
Signature miRNAs and their predicted targets in the opposite prognostic group.
ADAMTS5, BCHE, DCHS1, FIGN, FLJ10357, FLRT2, FZD7, HDAC4, MEIS2, NRP1, PDGFRA, PTPRD, RUNX1T1, SGCD, SVIL
C5orf23, PTGFRN, RPESP, RUNX1T1, SRR, THRB
ATP11C, C7orf42, CREBL2, DNAJA2, FRAT2, NFE2L3, NUP50, TFAP2C, WAPAL, ZNF655
C17orf63, EPB41, NMT1
NUP50, SFMBT1, WDR66, WNT2B, ZDHHC23, ZNF313
N4BP1, PHTF2, SLC45A3, WAPAL
AGPAT7, DLG3, NMT1, OSBPL3, RGS16, ROD1, ZNRF2
CREBL2, DNAJA2, KIAA1333, MBP, N4BP1, NUP50, PAFAH1B1, RNF138, WNT2B
CCDC88A, FRAT2, LBA1, MYCL1, PSME3, SNAP29, WAPAL, XPO6
ARFGEF2, ATP11C, CSNK1D, CTF8, OSBPL3, PAFAH1B1, PPTC7, RNF138, SDF2L1
The signature miRNAs in the same GCT prognosis group were found to target the same mRNAs. miR-503 and miR-543 both target PAFAH1B1 and RNF138, while miR-26a and miR-503 both target CREBL2 and DNAJA2 (Table 3, underlined). In addition, FRAT2 is a putative target of both miR-26a and miR-539, ATP11C is a target of both miR-26a and miR-543, NMT1 is a target of both miR-181c and miR-401, WNT2B is a target of both miR-218 and miR-503, N4BP1 is a target of both miR-335 and miR-503, and OSBPL3 is a target of both miR-410 and miR-543 (Table 3, underlined). Some mRNAs are even targeted by more than two miRNAs: NUP50 is targeted by three miRNAs (miR-26a, miR-218 and miR-503), while WAPAL is a target of four miRNAs (miR-26a, miR-335, miR-433 and miR-539 (Table 3, in bold and underlined, respectively). Thus it would seem that there are complex and highly interactive miRNA-mRNA genetic networks active in germinomas and NGMGCTs.
Functional module and pathway analysis as a framework for the interpretation of GCT biology
In contrast, the principal functions of the p-regulated genes in the NGMGCT group (IPG/PPG) of pediatric GCTs include those related to small GTPase (Rho protein especially) mediated signal transduction (Figure 3B, panel 1), cell motility (Figure 3B, panel 2) and various genes associated with active differentiation processes, in particular neuron differentiation (Figure 3B, panel 3). Seven genes involved in the Wnt receptor signaling pathway are also significantly active in this group (p = 1.07*10e-4; Figure 3B, panel 1). When the genes (q < 0.001) are subjected to a KEGG pathway database to obtain a similar module analysis using the DAVID 2008 web-based tool, the top-ranked canonical pathways in the NGMGCT group again include cell motility (such as Focal adhesion, ECM-receptor interaction and Gap junction), axon guidance and Wnt signaling (Figure 3C). Expression of Wnt pathway genes (such as FZDI, FZD3, FZD4, FZD5, FZD6 and SFRP1, SFRP2, FRZB, SFRP4) have been previously reported in a pluripotent human embryonal carcinoma cell line and in an embryonic stem cell , which supports the reliability of our functional module analysis. FZDI, FZD4, FZD7 and SFRP1 are also in our gene list (Table 2 and Additional file 2). The detailed locations of the signature genes are indicated in Additional file 3 and Additional file 4.
Chromosome locations of the differentially expressed genes and cytogenetic analysis of the GCTs
Gene set enrichment analysis (GSEA) was performed by DAVID for all chromosomal arms using the entire gene list. NGMGCTs were found to shows significantly transcript expression in the 7q21 cytoband region, which contains 3 NGMGCT genes: GNG11 (guanine nucleotide binding protein (G protein), gamma 11), GNAI1 (G protein alpha inhibiting activity polypeptide 1) and FZD1 (frizzled homolog 1). In germinomas, genes were overexpressed at Xq27.1, 14q32.1 (TCL1A & 1B), 1p36.11 (CCDC21, ZNF593, FAM46B and C1orf135), 12q13.13, 6p21.33 (ABCF1, HIST1H2BK and C6orf136) and 20q13.1-q13.2 (Figure 3D). The POU5F1 (OCT4) germinoma gene, as well as SLC4A8, LOC57228 and C12orf44, are overexpressed at chr12q13.13. The spermatogenesis associated gene SPATA2, as well as PTPN1, are overexpressed at 20q13.1-q13.2 (Figure 3D).
Deleted chromosomal regions in NGMGCTs and the genes within those regions.
ABCG2, ADAD1, ADH1A, ADH1B, ADH1C, ADH4, ADH5ADH6, ADH7, AFF1, AGPAT9, AGXT2L1, AIMP1, ALPK1, ANK2, ANKRD50, ANKRD56, ANTXR2, ANXA3, ANXA5, AP1AR, ARD1B, AREG, ARHGAP24, ARSJ, ART3, ATOH1, BANK1, BBS7, BBS12, BDH2, BMP2K, BMP3, BMPR1B, BTC, C4orf3, C4orf11, C4orf12, C4ord17, C4orf21, C4ord22, C4orf26, C4orf29, C4orf31, C4ord32, C4orf33, C4orf36, C4orf37, CAMK2D, CAPSP6, CCDC109B, CCDC158, CCNA2, CCNG2, CCN1, CDKL2, CDS1, CENPE, CEP170L, CFI, CISD2, CNOT6L, COL25A1, COPS4, COQ2, CXCL2, CXCL3, CXCL9, CXCL10, CXCL11, CXCL13, CXXC4, CTP2U1, DAPP1, DDIT4L, DKK2, DMP1, DNAJB14, DSPP, EEF1AL7, EGF, EIF4E, ELOVL6, EMCN, ENOPH1, ENPEP, EPGN, EREG, EXOSC9, FABP2, FAM13A, FAM13AOS, FAM47E, FAM175A, FAM190A, FAT4, FGF2, FGF5, FLJ20184, FRAS1, G3BP2, GAR1, GDEP, GK2, GPRIN3, GRID2, GSTCD, H2AAFZ, HADH, HELQ, HERC3, HERC5, HERC6, HNRPDL, HPGDS, HPSE, HSD17B11, HSD17B13, HSPA4L, IBSP, IL2, IL21, INTS12, INTU, KIAA1109, KLHL8, LARP1B, LARP7, LEF1, LIN54, LOC100192379, LOC256880, LOC285419, LOC285456, LOC641518, LOC729338, LRIT3, MAD2L1, MANBA, MAPK10, MAPKSP1, MEPE, METAP1, METTL14, MFSD8, MMRN1, MRPL1, MRPS18C, MTHFD2L, MTTP, MYOZ2, NAAA, NAP1L5, NDST3, NDST4, NEUROG2, NFKB1, NHEDC1, NHEDC2, NKX6-1, NPNT, NUDT6, NUDT9, NUP54, OSTC, PAPSS1, PAQP3, PARM1, PCNAP1, PDE5A, PDHA2, PDLIM5, PGRMC2, PHF17, PIGY, PITX2, PKD2, PLA2G12A, PLAC8, PLK4, PPA2, PPBPL2, PPEF2, PPM1K, PPP3CA, PRDM5, PRDM8, PRKG2, PRSS12, PTPN13, QRFPR, RAP1GDS1, RASGEF1B, RCHY1, RG9MTD2, RPL34, RRH, SCARB2, SCD5, SCLT1, SDAD1, SEC24B, SEC24D, SEC31A, SEP11, SGMS2, SHROOM3, SLC10A6, SLC25A31, SLC39A8, SMARCAD1, SNCA, SNHG8, SNORA24, SPARCL1, SPATA5, SPP1, SPRY1, *SYNPO2, TACR3, TBCK, TET2, THAP6, THAP9, TIFA, TIGD2, TMEM150C, TMEM155, TMSL3, TNIP3, TRAM1L1, TRPC3, TSPAN5, UBE2D3, YGT8, UNC5C, USO1, USP53, WDFY3
hsa-miR-302A, has-miR-302B, has-miR-302C, has-miR-302D, has-miR-367, has-miR-575, has-miR-577
ANKRE20A2, ANKRD20A3, ANKRD20A4, AQP7P1, AQP7P2, CBWD3, CBWD5, CBWD6, CCDC29, FAM27A, FAM27B, FAM27C, FAM74A4, FAM75A5, FAM75A7, FXOD4L2, FOXD4L3, FOXD4L4, FOXD4L5, FOXD4L6, KGFLP1, LOC100133920, LOC440839, LOC440896, LOC442421, MGC21881, PGM5P2
(No know ones)
Discussion and Conclusions
GCT is a specific type of CNS tumor with several subtypes. The two major forms of these tumors, germinoma (GPG) and NGMGCT (IPG/PPG), present with different clinical behaviors, differences in sensitivity to therapeutic regimens and different outcomes. The overall survival of patients with germinomas is significantly better than that of patients with NGMGCTs in our series (Figure 1A) and this is similar to other previously reported series [42, 43]. To explore the molecular difference between these two different histological/therapeutic prognostic groups, we have identified with confidence a number of differentially expressed miRNAs and mRNA; these permit an interpretation of the clinical survival variations and downstream hypothesis testing. The various divergent biological functions that correlate with the clinical observations are also revealed.
Among these miRNAs, miR-142-5p and miR-146a are upregulated in the pediatric germinomas (GP group) when compared to the NGMGCTs (IPG/PPG). Up to the present, no miRNA profile of pediatric GCTs has been published. A miRNome report on adult gonadal GCTs showed that, for each GCT subtype, the miRNA patterns are quite different . In their dataset, miR-142-5p and miR-146a are also more abundant in adult seminomas than in gonadal ECs . In addition, let-7e, miR-133b, miR-218 and miR-654-3p are also abundant in both pediatric NGMGCTs and adult ECs (Figure 1C) . However, the notable discrepancies are miR-181c and miR-218, the expression levels of which are more abundant in adult testicular seminomas but are lower in pediatric intracranial germinomas (Figure 1) . The unique expression pattern of these miRNAs in pediatric CNS GCTs may reflect the differences in pathogenesis mechanisms between adult and pediatric GCTs , or, alternatively, the variation in genetic makeup between Western and Taiwanese patients.
We also correlated the transcript levels of miRNAs to their candidate targets in order to identify microRNA-mRNA target pairs (Table 3). It has been shown that some miRNAs, such as miR-1, can downregulate the transcript levels of a large number of target genes in mammalian cells . Two large scale proteomic studies published very recently have shown that, although some microRNA target proteins are repressed without detectable changes in mRNA levels, more than a third of translational repressed targets also display detectable mRNA destabilization and, for the more highly repressed targets, mRNA destabilization usually makes up the major component of repression [19, 20]. Gene expression microarrays can therefore be, and have been, applied for the identification of downstream targets for miRNAs [44–46]. However, proof of direct binding between those miRNAs and target mRNAs, as well as the direct translational repression of target mRNAs, is still needed. Such confirmation will require more wetlab experiments such as immunoblotting and reporter assays.
When compared with NGMGCTs, the germinomas largely recapitulate the features of self-renewing pluripotent human embryonic stem (hES) cells, such as involvement of POU5F1 (OCT4), NANOG and KLF4 (q < 0.01). Both seminomas and embryonal carcinomas are known to express stem cell markers, such as POU5F1 and NANOG [47, 48]. In addition, in an attempt to find coordinated overexpressed gene clusters in GCTs, Korkola et al. found NANOG at chromosome 12p13.31 is overexpressed in undifferentiated (embryonal carcinomas and seminomas) tumors versus differentiated (teratoma, yolk sac tumor, and choriocarcinoma) tumors . By overexpressing POU5F1, NANOG and KLF4, it is now possible to reprogram the transcriptomes of somatic primary cells, which results in their dedifferentiation from matured cells to ES cell-like iPS (induced pluripotent stem) cells . The abundant expression of these dedifferentiation factors in germinomas therefore mirrors the more undifferentiated histopathological characteristics of these tumors. Whereas such similarities have previously been described for adult and pediatric seminomas [16, 17, 47, 48], we now know that this also applies to Asian pediatric CNS germinomas.
Although germinomas abundantly express the above three stemness factors, it is NGMGCTs (IPG/PPG) who show a closer gene expression pattern to ESCs (Figure 2C). This observation is consistent with pervious global gene expression reports whereby the gene expression patterns of human ES cell lines are similar to those of the human embryonal carcinoma cell samples but are more distantly related to those of seminoma samples . The close relationship between NGMGCTs and ES cells supports the hypothesis that germinomas are closely related to primordial germ cells (PGCs), and EC cells/NGMGCTs represent a reversion to a more ICM- or primitive ectoderm-like cell type . Whether germinomas and zygotes/blastomeres share similar mRNA or microRNA profiles is under investigation at present. The close relationship between NGMGCTs and ES cells may additionally be reflected in the worse prognosis for these tumors. Recently, via novel genomic approaches, it has been shown that aggressive and poor prognostic tumors, such as glioblastomas, inherit preferential ES cell gene expression profiles . The similarity between pediatric NGMGCTs and human ES cells may therefore reflect the clinical observation that CNS NGMGCTs are more malignant and show a higher fatality rate than germinomas.
The close relationship in genetic makeup between NGMGCTs and ESCs also suggest that factors other than POU5F1 (OCT4), NANOG or KLF4 are responsible for ESC gene expression. In this study, we found that two key epithelial-mesenchymal transition (EMT) regulators, SNAI2 (SLUG) and TWIST2, are abundantly expressed in the NGMGCT group (IPG/PPG) (Table 2 and Figure 2D). It has been reported that EMT transcription factors, SNAI1 (alias SNAIL) and TWIST, can independently dedifferentiate mammalian cancer cells and induces the generation of cancer stem-like cells, which then form mammospheres . It is possible that SNAI2 (SLUG) and TWIST2 behaves like Snail and TWIST and can introduce malignancy and stemness in pediatric GCTs. Targeting oncogenic stemness genes or EMT-related embryonic signaling pathways (such as the Wnt pathway, Figures 2D &3C) may differentiate a highly malignant NGMGCT into a more matured transcriptome type, thereby increasing the sensitivity of these tumors to the classical therapeutic regimen of radical resection, irradiation and chemotherapy, which would produce a better prognosis for the patients.
In addition to stemness genes (such as genes involved in reproduction and male gonad development), the germinomas were found to overexpress genes involved in the DNA damage checkpoint, which indicates active DNA integrity checking in the germinomas and thereby reflects why the clinical phenotype of germinomas has a better prognosis (Figure 3A). Among the other genes that were found to be expressed abundantly in germinomatous tissues were genes associated with the immune system process and this correlates with the abundant lymphocytic infiltration of germinomas found during histological observation. Relative to germinomas, we observed a significant enrichment of overexpression of differentiation and morphogenesis (especially neurogenesis) genes in NGMGCTs, which correlates with the differentiated state of these tumor cells (Figure 3B). There is also evidence of overexpression of genes in the Wnt/β-catenin pathway in our dataset (Figures 3B-C), which is consistent with previous studies of nonseminomatous malignant GCTs [15, 51]. In concordance with the higher recurrence and disseminating clinical behaviors of NGMGCTs, a significant enrichment for overexpression of motility, tight junction, focal adhesion, and adherent junction genes in NGMGCTs was observed (Figures 3B-C). Our results thereby integrate molecular profiles with clinical observations and provide a better understanding of the underlying molecular mechanisms. The combined targeting of hub genes involved in all these biological modules by a cocktail therapy-like regimen may eventually lead to an alleviation of these malignant CNS tumors.
During the submission of this manuscript, a very recent reference based on testis GCTs identified gene expression signatures that predicted outcomes in patients with extra-cranial adult GCTs . We compared the age and tumor characteristics between our series against the genomic study group of CNS GCTs in children and the reported study of extra CNS GCTs in adult men (Additional file 1-C) . In our series and the genomic study of CNS GCTs, both germinomas and NGGCTs in children younger than 18 years old were included, whereas Korkola's study involved adult men with nonseminomatous GCTs (NSGCTs) . In our series, 118 tumors were pure germinomas or tumors with a germinoma component, 49 tumors were pure teratoma or tumors with a teratoma component, and 27 cases were classified as YSTs including 10 pure YSTs, 11 tumors with a YST component, and 6 cases with serum AFP elevation (pure immature teratomas excluded). Among the 21 cases with genomic studies, 9 tumors were pure germinomas, 2 tumors were pure mature teratomas, and 9 tumors were mixed GCTs, including one mature teratoma with serum AFP elevation and one germinoma with serum AFP elevation. The correlation of tumor characteristics between the studies of Korkola et al. and ours in Additional file 1-C constituted the basis for the comparison of genomic molecular findings across the different therapeutic prognostic groups and histology between these two studies.
Korkola et al. concluded that using a 140-gene signature, they could predict 5-year overall survival (OS) (p < 0.001) . Both our study and that of Korkola et al. identified good outcome GCTs express gene sets involved in immune function and the repression of differentiation (such as POU5F1/OCT4), while poor outcome GCTs express genes involved in active differentiation (in particular, neuron differentiation) (Fig. 3) . A 10-gene prognosis model was also built using a univariate Cox model. When the samples were dichotomized by median score, there was significant separation of the survival curves (p < 0.002) . These 10 genes were STX6, CFLAR, FNBP1, ITSN2, SYNE1, MAP3K5, PTGDS, PXMP2, IRAK4, and RABGAP1L . Among these 10 genes STX6 (syntaxin 6) and CFLAR (CASP8 and FADD-like apoptosis regulator) are over-expressed in our germinoma group (q < 0.01). It will be interesting to fit their prognosis signatures onto our dataset to see whether GCTs of different anatomic locations, ages and ethnic populations express similar prognosis genes. However, since all the tissues used in our study were freshly collected over the last 2 years, only one death has been recorded so far (Additional file 1). As a result, this work needs to be carried out at a later stage.
The variation in chromosome copy number variation (CNV) regions between germinomas and NGMGCTs were mapped to cytobands 4q13.3-4q28.3 and 9p11.2-9q13 (Figure 4). Chromosome abnormality analysis of adult testicular germ cell tumors (tGCTs) revealed that all GCTs show 12p gain [25, 26]. In 2007, Palmer et al. used metaphase-based comparative genomic hybridization (CGH) to analyze genomic imbalance in 34 pediatric GCTs (22 yolk sac tumors (YSTs), 11 germinomatous tumors and one metastatic embryonal carcinoma). The YSTs showed an increased frequency of 1p loss (p = 0.003), 3p gain (p = 0.02), 4q loss (p = 0.07) and 6q loss (p = 0.004) compared to germinomas . Most of their cases were from the testis, the ovary or the sacrococcygeal region and only 2 germinomas and 1 YST brain GCTs were included ; this is a possible explanation of the discrepancies between their results and ours. We also observed 4q loss in the NGMGCTs (including YSTs), suggesting that genomic imbalance in this region, and the genes/miRNAs encoded by this chromosomal region, may play a crucial tumor suppressing role during NGMGCT pathogenesis and affect clinical performance (Table 4). Six genes (BANK1, CXCL9, CXCL11, DDIT4L, ELOVL6 and HERC5) within 4q13.3-4q28.3 showed higher expression levels in the germinomas (Table 4). DDIT4L, ELOVL6 and HERC5 are among the top 50 highly expressed genes in germinomas (Table 1). A putative GCT tumor suppressor gene SYNPO2 (Synaptopodin 2), also known as myopodin, is also within the 4q13.3-4q28.3 deletion region (Table 4). SYNPO2 has recently been shown to have the highest predictive value when assessing 5-year overall survival , which is consistent with a possible role as a tumor suppressor. However, we do not observe differential SYNPO2 expression between NGMGCTs and germinomas (Table 4). It is unclear whether SYNPO2 expression is also downregulated in Taiwanese germinomas compared to normal brains. In addition, whether survival predictors derived from Western cases can be applied to Asian patients still awaits elucidation.
Recently two independent genome-wide association studies (GWAS) have reported on susceptibility loci associated with tGCT: Kanetsky et al. mapped seven markers at 12p22 near KITLG (c-KIT ligand) and two markers at 5q31.3 near SPRY4 (sprouty 4) ; furthermore Rapley et al. identified loci on chromosome 5, 6 and 12 . A third locus, in an intron of BAK1, a gene that promotes apoptosis, was also identified by Rapley et al. . Similarly, the CGH profiles in childhood GCTs have been reported to resemble those in adults [55, 56]. In terms of cytogenetics differences between the different histological entities, loss of chromosome 19 and 22 material and gain of 5q14-q23, 6q21-q24 and 13q material were found to occur at a significantly lower frequency in seminoma adult tGCTs compared to non-seminoma adult tGCTs . Among Taiwanese pediatric GCTs, no common copy number variation (CNV) could be found in either the germinomas or the mature teratomas (Figure 4). The divergence between our results and published Caucasian ones may be partly due to the different ethnic samples used, the application of different bioinformatics algorithms and the fact that we compared the differences between germinomas and NGMGCTs but not common aberrations across all GCTs.
In summary we have identified miRNome, mRNA signatures and CNV regions that are associated with two pediatric GCT histological entities (germinoma and NGMGCTs) and two prognostic groups (GPG and IPG/PPG). The clinical discrepancies between the two histological entities (germinomas of GPG and NGMGCTs of IPG/PPG) are therefore mirrored by their differences in global transcriptome patterns and their unique stem cell traits. One of the interesting questions that remain is whether pediatric GCTs from other ethnic background also express similar transcriptome traits and CNV regions. If Caucasian and Taiwanese GCTs possess unique transcriptome traits, therapeutic and diagnostic experience from Western countries may not be applicable directly to Asian or Taiwanese patients. Therefore, the genes and miRNAs identified here hold the potential of being novel therapeutic targets and may be used for further differentiation therapy. The Wnt pathway, for example, is activated in NGMGCTs (Figure 3C), and drugs targeting this specific pathway may hold potential as a treatment approach to NGMGCTs. Transdifferentiating ESC-like NGMGCTs into a benign status may also be a novel and useful tactic against these fatal pediatric tumors.
Patient details and microarray expression data
All procedures were approved by the Institutional Review Board of the Taipei Veteran General Hospital, Taiwan and informed consent was obtained from each subject or the subject's guardian according to the Helsinki Declaration. In this study, we reviewed a clinical database containing 176 cases of primary pediatric CNS GCTs involving patients less than 18 years old; the database was collected from 1970 to 2007 at Taipei Veterans General Hospital (Taipei VGH). Among them, RNA samples from the hospital tissue bank were obtained in 13 cases, and mRNA and miRNA microarray analysis were performed in 13 cases and 12 cases respectively. The histological types of this series of 176 primary CNS GCTs and other selected clinical data are summarized in Additional file 1-A. Excluding operative mortality, the overall survival rates of the 95 germinoma cases and 59 NGMGCT cases that form this series were studied to support the difference in malignancy and outcome between these two groups of CNS GCTs. Overall survival was analyzed by the Kaplan-Meier method, and the log-rank test was applied to compare the cumulative survival durations in the different patient groups and this was done using SPSS statistics software (SPSS Inc., Chicago, Illinois, USA).
The clinical features of the 22 CNS GCT cases used in microarray studies are listed in Additional file 1-B in order to help correlation with the results of the genomic analysis. In the transcriptome analysis, 13 cases had both mRNA and miRNA analyzed, except that case 7 had only mRNA analyzed (Additional file 1-B); the latter was due to insufficient RNA being available. The histological subtypes in the dataset are germinoma (6), mixed GCT of germinoma and mature teratoma (1), immature teratoma (1), mixed GCTs of NGMGCTs category (4), YST (1). Caucasian embryonic stem cell (ESC) array data that had been previously published , and the array data of Taiwanese ESC line hES-T3 (T3ES) were downloaded from the Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/) database (accession number GSE9440) . All ESC and GCT mRNA array data were implemented using the Affymetrix Human Genome U133 Plus 2.0 chips. The ESC array dataset was downloaded from GEO datasets GSE7234, GSE7896, GSE9440 (for Taiwanese ESC lines) together with GSE9832 and GSE13828. All GCT raw array data (including gene expression array, microRNA array and SNP array) are available from the GEO database (accession number GSE19350).
MicroRNA microarray and data analysis
The Agilent Human miRNA Microarray Kit V2 (Agilent, Foster City, CA, USA) containing probes for 723 human microRNAs from the Sanger database v10.1 was used. GeneSpring GX 9 software (Agilent, USA) was used for value extraction. A 2-tailed Student's t-test was then used for the calculation of the p value for each miRNA probe. Principal component analysis (PCA) was performed using the Partek Genomics Suite software http://www.partek.com to provide a visual impression of how the various sample groups are related. To predict the downstream mRNA targets of the miRNAs, the TargetScan web tool http://genes.mit.edu/targetscan/index.html was used. The miRNA-target pairs were then mapped by examining whether there were any candidate miRNA target genes whose expressions became diminished in a given group of tumors while there was overexpression of the correlated miRNAs. A Fisher's exact test was used to examine whether the associations obtained were by chance or not.
Copy number variation (CNV)
The materials used in the CNV study were fresh frozen tumor tissues, and the genomic DNA from each sample was isolated using a DNeasy Blood & Tissue Kit according to the manufacturer's instructions (Qiagen, GmbH, Germany). The Human610-Quad Beadchip (Illumina Technologies, USA) with 550,000 selected tag SNPs and 60,000 genetic markers covering 4.7 KB mean probe spatial resolution was used for the analysis. Normalized bead intensity data obtained for each sample were loaded into the Illumina BeadStudio™ software version 188.8.131.52, which calculated CNV data from Intensity and B allele frequency. The calculated results were then exported to Partek Genomics Suite software. Chromosome abnormalities were identified by the cnvPartition algorithm using the default threshold provided by the BeadStudio software and finally visualized by the Partek Genomics Suite v6.4 http://www.partek.com/. A copy number baseline dataset containing 125 Human 1 M HapMap samples (generated by the Partek Inc.) was used to identify aberrant chromosomal regions in GCTs.
Gene expression microarray probe preparation and data analysis
Total RNA collection, cRNA probe preparation, array hybridization and data analysis were done as described previously . In brief, fresh tissues were immersed in Trizol™ solution (Invitrogen Inc., Carlsbad, CA, USA) and total RNA, including the small RNA fraction, were extracted and precipitated according to the manufacture's instructions. RMA log expression units were calculated from Affymetrix™ HG-U133 Plus 2.0 whole genome array data using the 'affy' package included in the Bioconductor http://www.bioconductor.org suite of software for the R statistical programming language http://www.r-project.org. The default RMA settings were used to background correct, normalize and summarize all expression values. Significant differences between the sample groups was identified using the 'limma' (Linear Models for Microarray Analysis) package of the Bioconductor suite, and an empirical Bayesian moderated t-statistic hypothesis test between the two specified phenotypic groups was performed . To control for multiple testing errors, we then applied a false discovery rate algorithm to these p values in order to calculate a set of q values, thresholds of the expected proportion of false positives, or false rejections of the null hypothesis .
Heat maps were created by the dChip software http://www.dchip.org/. Classical multidimensional scaling (MDS) was performed using the standard function of the R program to provide a visual impression of how the various sample groups are related. Gene annotation was performed by the ArrayFusion web tool http://microarray.ym.edu.tw/tools/arrayfusion/. Gene enrichment analysis was performed by the Gene Ontology (GO) and KEGG databases using the WebGestalt http://bioinfo.vanderbilt.edu/webgestalt/ and DAVID Bioinformatics Resources 2008 http://david.abcc.ncifcrf.gov/ interfaces, respectively. The Euclidean distance between two groups of samples is calculated by the average linkage measure (the mean of all pair-wise distances (linkages) between members of the two groups concerned) . The standard error of the average linkage distance between two groups (the standard deviation of pair-wise linkages divided by the square root of the number of linkages) is quoted when inter-group distances are compared in the text.
Real-time quantitative polymerase chain reaction
Between 100 ng to 1 μg of total RNA was used to perform reverse transcription (RT) using the RevertAid™ Reverse transcriptase kit (Cat. K1622; Fermentas, Glen Burnie, Maryland, USA) as directed by the manufacturer. Real-time PCR reactions were performed using Maxima™ SYBR Green qPCR Master Mix (Cat. K0222; Fermentas, Glen Burnie, Maryland, USA), and the specific products were detected and analyzed using the StepOne™ sequence detector (Applied Biosystems, USA). The expression level of each microRNA was normalized to the expression level of U6 small nuclear RNA, while the expression level of each gene was normalized to GAPDH expression. For hsa-miR-142-5p, the forward primer was 5'-CGCCGGCATAAAGTAGAAAGC-3' and the reverse transcription primer was 5'-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACAGTAGT-3'. For hsa-miR-335, the forward primer was 5'-GGCGTCAAGAGCAATAACGAA-3' and the reverse transcription primer was 5'-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACACATTT-3'. For has-miR-654-3p, the forward primer was 5'-GCGCTATGTCTGCTGACCAT-3' and the reverse transcription primer was 5'-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGAAAGGTG-3'. For U6, the forward primer was 5'-CTCGCTTCGGCAGCAC-3' and the reverse primer was 5'-AACGCTTCACGAATTTGCG-'3'. For NANOG, the forward primer was 5'-AGAACTCTCCAACATCCTGAACCT-3' and the reverse primer was 5'-TGCCACCTCTTAGATTTCATTCTCT-3'. For SNAI2 (alias SLUG), the forward primer was 5'-TGACAGGCATGGAGTAACTCTCA-3' and the reverse primer was 5'-AAATGCTGGAGAACTGGAAAG-3'. For POU5F1 (alias OCT4), the forward primer was 5'-CGGAGGAGTCCCAGGACAT-3' and the reverse primer was 5'-CCCACATCGGCCTGTGTATAT. For GAPDH, the forward primer was 5'-CCAGCCGAGCCACATCGCTC-3' and the reverse primer was 5'-ATGAGCCCCAGCCTTCTCCAT-3'.
The authors acknowledge Dr. Chih-Hung Jen for technical support, and the array services provided by Microarray & Gene Expression Analysis Core Facility of the National Yang-Ming University VGH Genome Research Center (VYMGC). The Gene Expression Analysis Core Facility is supported by the National Research Program for Genomic Medicine, National Science Council (NSC). We also thank Dr. Ralph Kirby for the language revision of the manuscript. This work is supported by Yang-Ming University (a grant from Ministry of Education, Aim for the Top University Plan), Taipei Veterans General Hospital Reserch Fund, VGHUST Joint research Program, Tsou's Foundation (V98ER2-003, V98ER2-019, V96C1-133, V97C1-116, V98C1-002, V98S1-017, and 98A-C-T506), NSC (NSC97-3111-B-010-004, NSC98-2320-B-010-020-MY3 and NSC96-2314-B-075-012-MY3), and partly by the National Health Research Institute (NHRI-EX97-9704BI).
- Kuratsu J, Ushio Y: Epidemiological study of primary intracranial tumors in childhood. A population-based survey in Kumamoto Prefecture, Japan. Pediatr Neurosurg. 1996, 25 (5): 240-246. 10.1159/000121132. discussion 247PubMedView ArticleGoogle Scholar
- Rickert CH, Paulus W: Epidemiology of central nervous system tumors in childhood and adolescence based on the new WHO classification. Childs Nerv Syst. 2001, 17 (9): 503-511. 10.1007/s003810100496.PubMedView ArticleGoogle Scholar
- Cho KT, Wang KC, Kim SK, Shin SH, Chi JG, Cho BK: Pediatric brain tumors: statistics of SNUH, Korea (1959-2000). Childs Nerv Syst. 2002, 18 (1-2): 30-37. 10.1007/s00381-001-0547-y.PubMedView ArticleGoogle Scholar
- Committee of Brain Tumor Registry of J: Report of Brain Tumor Registry of Japan (1969-1996). Neurol Med Chir (Tokyo). 2003, 43 (Suppl): i-vii. 1-111Google Scholar
- Wong TT, Ho DM, Chang KP, Yen SH, Guo WY, Chang FC, Liang ML, Pan HC, Chung WY: Primary pediatric brain tumors: statistics of Taipei VGH, Taiwan (1975-2004). Cancer. 2005, 104 (10): 2156-2167. 10.1002/cncr.21430.PubMedView ArticleGoogle Scholar
- Matsutani M, Japanese Pediatric Brain Tumor Study Group: Combined chemotherapy and radiation therapy for CNS germ cell tumors--the Japanese experience. J Neurooncol. 2001, 54 (3): 311-316. 10.1023/A:1012743707883.PubMedView ArticleGoogle Scholar
- Echevarria ME, Fangusaro J, Goldman S: Pediatric central nervous system germ cell tumors: a review. Oncologist. 2008, 13 (6): 690-699. 10.1634/theoncologist.2008-0037.PubMedView ArticleGoogle Scholar
- Matsutani M: Clinical management of primary central nervous system germ cell tumors. Semin Oncol. 2004, 31 (5): 676-683. 10.1053/j.seminoncol.2004.07.010.PubMedView ArticleGoogle Scholar
- Matsutani M, Sano K, Takakura K, Fujimaki T, Nakamura O, Funata N, Seto T: Primary intracranial germ cell tumors: a clinical analysis of 153 histologically verified cases. J Neurosurg. 1997, 86 (3): 446-455. 10.3171/jns.1997.86.3.0446.PubMedView ArticleGoogle Scholar
- Sano K, Matsutani M, Seto T: So-called intracranial germ cell tumours: personal experiences and a theory of their pathogenesis. Neurol Res. 1989, 11 (2): 118-126.PubMedGoogle Scholar
- Packer RJ, Cohen BH, Cooney K: Intracranial germ cell tumors. Oncologist. 2000, 5 (4): 312-320.PubMedGoogle Scholar
- Sperger JM, Chen X, Draper JS, Antosiewicz JE, Chon CH, Jones SB, Brooks JD, Andrews PW, Brown PO, Thomson JA: Gene expression patterns in human embryonic stem cells and human pluripotent germ cell tumors. Proc Natl Acad Sci USA. 2003, 100 (23): 13350-13355. 10.1073/pnas.2235735100.PubMed CentralPubMedView ArticleGoogle Scholar
- Werbowetski-Ogilvie TE, Bhatia M: Pluripotent human stem cell lines: what we can learn about cancer initiation. Trends Mol Med. 2008, 14 (8): 323-332. 10.1016/j.molmed.2008.06.005.PubMedView ArticleGoogle Scholar
- Josephson R, Ording CJ, Liu Y, Shin S, Lakshmipathy U, Toumadje A, Love B, Chesnut JD, Andrews PW, Rao MS, Auerbach JM: Qualification of embryonal carcinoma 2102Ep as a reference for human embryonic stem cell research. Stem Cells. 2007, 25 (2): 437-446. 10.1634/stemcells.2006-0236.PubMedView ArticleGoogle Scholar
- Walsh J, Andrews PW: Expression of Wnt and Notch pathway genes in a pluripotent human embryonal carcinoma cell line and embryonic stem cell. APMIS. 2003, 111 (1): 197-210. 10.1034/j.1600-0463.2003.1110124.x. discussion 210-191PubMedView ArticleGoogle Scholar
- Korkola JE, Houldsworth J, Chadalavada RS, Olshen AB, Dobrzynski D, Reuter VE, Bosl GJ, Chaganti RS: Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors. Cancer Res. 2006, 66 (2): 820-827. 10.1158/0008-5472.CAN-05-2445.PubMedView ArticleGoogle Scholar
- Palmer RD, Barbosa-Morais NL, Gooding EL, Muralidhar B, Thornton CM, Pett MR, Roberts I, Schneider DT, Thorne N, Tavare S, Nicholson JC, Coleman N, Children's Cancer and Leukaemia Group: Pediatric malignant germ cell tumors show characteristic transcriptome profiles. Cancer Res. 2008, 68 (11): 4239-4247. 10.1158/0008-5472.CAN-07-5560.PubMedView ArticleGoogle Scholar
- Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS, Johnson JM: Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005, 433 (7027): 769-773. 10.1038/nature03315.PubMedView ArticleGoogle Scholar
- Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP: The impact of microRNAs on protein output. Nature. 2008, 455 (7209): 64-71. 10.1038/nature07242.PubMed CentralPubMedView ArticleGoogle Scholar
- Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N: Widespread changes in protein synthesis induced by microRNAs. Nature. 2008, 455 (7209): 58-63. 10.1038/nature07228.PubMedView ArticleGoogle Scholar
- Ferretti E, De Smaele E, Po A, Di Marcotullio L, Tosi E, Espinola MS, Di Rocco C, Riccardi R, Giangaspero F, Farcomeni A, Nofroni I, Laneve P, Gioia U, Caffarelli E, Bozzoni I, Screpanti I, Gulino A: MicroRNA profiling in human medulloblastoma. Int J Cancer. 2009, 124 (3): 568-577. 10.1002/ijc.23948.PubMedView ArticleGoogle Scholar
- Ferretti E, De Smaele E, Miele E, Laneve P, Po A, Pelloni M, Paganelli A, Di Marcotullio L, Caffarelli E, Screpanti I, Bozzoni I, Gulino A: Concerted microRNA control of Hedgehog signalling in cerebellar neuronal progenitor and tumour cells. EMBO J. 2008, 27 (19): 2616-2627. 10.1038/emboj.2008.172.PubMed CentralPubMedView ArticleGoogle Scholar
- Chen Y, Stallings RL: Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res. 2007, 67 (3): 976-983. 10.1158/0008-5472.CAN-06-3667.PubMedView ArticleGoogle Scholar
- Gillis AJ, Stoop HJ, Hersmus R, Oosterhuis JW, Sun Y, Chen C, Guenther S, Sherlock J, Veltman I, Baeten J, Spek van der PJ, de Alarcon P, Looijenga LH: High-throughput microRNAome analysis in human germ cell tumours. J Pathol. 2007, 213 (3): 319-328. 10.1002/path.2230.PubMedView ArticleGoogle Scholar
- Summersgill B, Goker H, Weber-Hall S, Huddart R, Horwich A, Shipley J: Molecular cytogenetic analysis of adult testicular germ cell tumours and identification of regions of consensus copy number change. Br J Cancer. 1998, 77 (2): 305-313.PubMed CentralPubMedView ArticleGoogle Scholar
- Moran CA, Suster S, Koss MN: Primary germ cell tumors of the mediastinum: III. Yolk sac tumor, embryonal carcinoma, choriocarcinoma, and combined nonteratomatous germ cell tumors of the mediastinum--a clinicopathologic and immunohistochemical study of 64 cases. Cancer. 1997, 80 (4): 699-707. 10.1002/(SICI)1097-0142(19970815)80:4<699::AID-CNCR8>3.0.CO;2-I.PubMedView ArticleGoogle Scholar
- Mostert M, Rosenberg C, Stoop H, Schuyer M, Timmer A, Oosterhuis W, Looijenga L: Comparative genomic and in situ hybridization of germ cell tumors of the infantile testis. Lab Invest. 2000, 80 (7): 1055-1064.PubMedView ArticleGoogle Scholar
- van Echten J, Timmer A, Veen van der AY, Molenaar WM, de Jong B: Infantile and adult testicular germ cell tumors. a different pathogenesis?. Cancer Genet Cytogenet. 2002, 135 (1): 57-62. 10.1016/S0165-4608(01)00643-4.PubMedView ArticleGoogle Scholar
- Zahn S, Sievers S, Alemazkour K, Orb S, Harms D, Schulz WA, Calaminus G, Gobel U, Schneider DT: Imbalances of chromosome arm 1p in pediatric and adult germ cell tumors are caused by true allelic loss: a combined comparative genomic hybridization and microsatellite analysis. Genes Chromosomes Cancer. 2006, 45 (11): 995-1006. 10.1002/gcc.20363.PubMedView ArticleGoogle Scholar
- Palmer RD, Foster NA, Vowler SL, Roberts I, Thornton CM, Hale JP, Schneider DT, Nicholson JC, Coleman N: Malignant germ cell tumours of childhood: new associations of genomic imbalance. Br J Cancer. 2007, 96 (4): 667-676. 10.1038/sj.bjc.6603602.PubMed CentralPubMedView ArticleGoogle Scholar
- Kader AK, Liu J, Shao L, Dinney CP, Lin J, Wang Y, Gu J, Grossman HB, Wu X: Matrix metalloproteinase polymorphisms are associated with bladder cancer invasiveness. Clin Cancer Res. 2007, 13 (9): 2614-2620. 10.1158/1078-0432.CCR-06-1187.PubMedView ArticleGoogle Scholar
- Kawase A, Ishii G, Nagai K, Ito T, Nagano T, Murata Y, Hishida T, Nishimura M, Yoshida J, Suzuki K, Ochiai A: Podoplanin expression by cancer associated fibroblasts predicts poor prognosis of lung adenocarcinoma. Int J Cancer. 2008, 123 (5): 1053-1059. 10.1002/ijc.23611.PubMedView ArticleGoogle Scholar
- Takahashi K, Yamanaka S: Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006, 126 (4): 663-676. 10.1016/j.cell.2006.07.024.PubMedView ArticleGoogle Scholar
- Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA: Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007, 318 (5858): 1917-1920. 10.1126/science.1151526.PubMedView ArticleGoogle Scholar
- Katoh Y, Katoh M: Hedgehog signaling, epithelial-to-mesenchymal transition and miRNA (review). Int J Mol Med. 2008, 22 (3): 271-275.PubMedGoogle Scholar
- Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, Weinberg RA: An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet. 2008, 40 (5): 499-507. 10.1038/ng.127.PubMed CentralPubMedView ArticleGoogle Scholar
- Parathath SR, Mainwaring LA, Fernandez LA, Campbell DO, Kenney AM: Insulin receptor substrate 1 is an effector of sonic hedgehog mitogenic signaling in cerebellar neural precursors. Development. 2008, 135 (19): 3291-3300. 10.1242/dev.022871.PubMed CentralPubMedView ArticleGoogle Scholar
- Rubin R, Arzumanyan A, Soliera AR, Ross B, Peruzzi F, Prisco M: Insulin receptor substrate (IRS)-1 regulates murine embryonic stem (mES) cells self-renewal. J Cell Physiol. 2007, 213 (2): 445-453. 10.1002/jcp.21185.PubMed CentralPubMedView ArticleGoogle Scholar
- Pinson L, Auge J, Audollent S, Mattei G, Etchevers H, Gigarel N, Razavi F, Lacombe D, Odent S, Le Merrer M, Amiel J, Munnich A, Meroni G, Lyonnet S, Vekemans M, Attie-Bitach T: Embryonic expression of the human MID1 gene and its mutations in Opitz syndrome. J Med Genet. 2004, 41 (5): 381-386. 10.1136/jmg.2003.014829.PubMed CentralPubMedView ArticleGoogle Scholar
- Harris MA, Clark J, Ireland A, Lomax J, Ashburner M, Foulger R, Eilbeck K, Lewis S, Marshall B, Mungall C, Richter J, Rubin GM, Blake JA, Bult C, Dolan M, Drabkin H, Eppig JT, Hill DP, Ni L, Ringwald M, Balakrishnan R, Cherry JM, Christie KR, Costanzo MC, Dwight SS, Engel S, Fisk DG, Hirschman JE, Hong EL, Nash RS, Sethuraman A, Theesfeld CL, Botstein D, Dolinski K, Feierbach B, Berardini T, Mundodi S, Rhee SY, Apweiler R, Barrell D, Camon E, Dimmer E, Lee V, Chisholm R, Gaudet P, Kibbe W, Kishore R, Schwarz EM, Sternberg P, Gwinn M, Hannick L, Wortman J, Berriman M, Wood V, de la Cruz N, Tonellato P, Jaiswal P, Seigfried T, White R, Gene Ontology Consortium: The Gene Ontology (GO) database and informatics resource. Nucleic Acids Res. 2004, D258-261. 32 Database
- Zhang B, Kirov S, Snoddy J: WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res. 2005, W741-748. 10.1093/nar/gki475. 33 Web Server
- Moran CA, Suster S, Przygodzki RM, Koss MN: Primary germ cell tumors of the mediastinum: II. Mediastinal seminomas--a clinicopathologic and immunohistochemical study of 120 cases. Cancer. 1997, 80 (4): 691-698. 10.1002/(SICI)1097-0142(19970815)80:4<691::AID-CNCR7>3.0.CO;2-Q.PubMedView ArticleGoogle Scholar
- Ulbright TM: Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues. Mod Pathol. 2005, 18 (Suppl 2): S61-79. 10.1038/modpathol.3800310.PubMedView ArticleGoogle Scholar
- Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M, Ferlito M, Lowenstein CJ, Arking DE, Beer MA, Maitra A, Mendell JT: Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 2007, 26 (5): 745-752. 10.1016/j.molcel.2007.05.010.PubMed CentralPubMedView ArticleGoogle Scholar
- Liu T, Papagiannakopoulos T, Puskar K, Qi S, Santiago F, Clay W, Lao K, Lee Y, Nelson SF, Kornblum HI, Doyle F, Petzold L, Shraiman B, Kosik KS: Detection of a microRNA signal in an in vivo expression set of mRNAs. PLoS ONE. 2007, 2 (8): e804-10.1371/journal.pone.0000804.PubMed CentralPubMedView ArticleGoogle Scholar
- Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T: MicroRNA expression profiling in prostate cancer. Cancer Res. 2007, 67 (13): 6130-6135. 10.1158/0008-5472.CAN-07-0533.PubMedView ArticleGoogle Scholar
- Almstrup K, Hoei-Hansen CE, Wirkner U, Blake J, Schwager C, Ansorge W, Nielsen JE, Skakkebaek NE, Rajpert-De Meyts E, Leffers H: Embryonic stem cell-like features of testicular carcinoma in situ revealed by genome-wide gene expression profiling. Cancer Res. 2004, 64 (14): 4736-4743. 10.1158/0008-5472.CAN-04-0679.PubMedView ArticleGoogle Scholar
- de Jong J, Looijenga LH: Stem cell marker OCT3/4 in tumor biology and germ cell tumor diagnostics: history and future. Crit Rev Oncog. 2006, 12 (3-4): 171-203.PubMedView ArticleGoogle Scholar
- Shi Y, Desponts C, Do JT, Hahm HS, Scholer HR, Ding S: Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule compounds. Cell Stem Cell. 2008, 3 (5): 568-574. 10.1016/j.stem.2008.10.004.PubMedView ArticleGoogle Scholar
- Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008, 133 (4): 704-715. 10.1016/j.cell.2008.03.027.PubMed CentralPubMedView ArticleGoogle Scholar
- Fritsch MK, Schneider DT, Schuster AE, Murdoch FE, Perlman EJ: Activation of Wnt/beta-catenin signaling in distinct histologic subtypes of human germ cell tumors. Pediatr Dev Pathol. 2006, 9 (2): 115-131. 10.2350/08-05-0097.1.PubMedView ArticleGoogle Scholar
- Korkola JE, Houldsworth J, Feldman DR, Olshen AB, Qin LX, Patil S, Reuter VE, Bosl GJ, Chaganti RS: Identification and validation of a gene expression signature that predicts outcome in adult men with germ cell tumors. J Clin Oncol. 2009, 27 (31): 5240-5247. 10.1200/JCO.2008.20.0386.PubMed CentralPubMedView ArticleGoogle Scholar
- Kanetsky PA, Mitra N, Vardhanabhuti S, Li M, Vaughn DJ, Letrero R, Ciosek SL, Doody DR, Smith LM, Weaver J, Albano A, Chen C, Starr JR, Rader DJ, Godwin AK, Reilly MP, Hakonarson H, Schwartz SM, Nathanson KL: Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. Nat Genet. 2009, 41 (7): 811-815. 10.1038/ng.393.PubMed CentralPubMedView ArticleGoogle Scholar
- Rapley EA, Turnbull C, Al Olama AA, Dermitzakis ET, Linger R, Huddart RA, Renwick A, Hughes D, Hines S, Seal S, Morrison J, Nsengimana J, Deloukas P, UK Testicular Cancer Collaboration, Rahman N, Bishop DT, Easton DF, Stratton MR: A genome-wide association study of testicular germ cell tumor. Nat Genet. 2009, 41 (7): 807-810. 10.1038/ng.394.PubMed CentralPubMedView ArticleGoogle Scholar
- Stock C, Ambros IM, Lion T, Haas OA, Zoubek A, Gadner H, Ambros PF: Detection of numerical and structural chromosome abnormalities in pediatric germ cell tumors by means of interphase cytogenetics. Genes Chromosomes Cancer. 1994, 11 (1): 40-50. 10.1002/gcc.2870110107.PubMedView ArticleGoogle Scholar
- Kraggerud SM, Szymanska J, Abeler VM, Kaern J, Eknaes M, Heim S, Teixeira MR, Trope CG, Peltomaki P, Lothe RA: DNA copy number changes in malignant ovarian germ cell tumors. Cancer Res. 2000, 60 (11): 3025-3030.PubMedGoogle Scholar
- Huang TS, Hsieh JY, Wu YH, Jen CH, Tsuang YH, Chiou SH, Partanen J, Anderson H, Jaatinen T, Yu YH, Wang HW: Functional network reconstruction reveals somatic stemness genetic maps and dedifferentiation-like transcriptome reprogramming induced by GATA2. Stem Cells. 2008, 26 (5): 1186-1201. 10.1634/stemcells.2007-0821.PubMedView ArticleGoogle Scholar
- Li SS, Liu YH, Tseng CN, Chung TL, Lee TY, Singh S: Characterization and gene expression profiling of five new human embryonic stem cell lines derived in Taiwan. Stem Cells Dev. 2006, 15 (4): 532-555. 10.1089/scd.2006.15.532.PubMedView ArticleGoogle Scholar
- Wang HW, Trotter MW, Lagos D, Bourboulia D, Henderson S, Makinen T, Elliman S, Flanagan AM, Alitalo K, Boshoff C: Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat Genet. 2004, 36 (7): 687-693. 10.1038/ng1384.PubMedView ArticleGoogle Scholar
- Smyth GK: Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004, 3 (1): Article3Google Scholar
- Storey JD, Tibshirani R: Statistical significance for genomewide studies. Proc Natl Acad Sci USA. 2003, 100 (16): 9440-9445. 10.1073/pnas.1530509100. Epub 2003 Jul 9425PubMed CentralPubMedView ArticleGoogle Scholar
- Yang TP, Chang TY, Lin CH, Hsu MT, Wang HW: ArrayFusion: a web application for multi-dimensional analysis of CGH, SNP and microarray data. Bioinformatics. 2006, 22 (21): 2697-2698. 10.1093/bioinformatics/btl457.PubMedView ArticleGoogle Scholar
- Dennis G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA: DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003, 4 (5): P3-10.1186/gb-2003-4-5-p3.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.